Revance (formerly Crown Laboratories)

Revance is the current operating name of the privately held company created after Crown Laboratories acquired Revance Therapeutics, Inc. in February 2025. Crown then announced that the combined company would operate under the Revance name from March 31, 2025. This sequence matters: Crown was the acquirer, but Revance is the current corporate brand. (acquisition announcement; name-transition announcement)

For the botulinum toxin market, Revance is most relevant as the developer and current company context for Daxxify, whose nonproprietary name is daxibotulinumtoxinA-lanm. Corporate renaming did not change Daxxify’s product identity, U.S. indications, or product-specific potency units.

Quick Answers

Question	Short answer
What is Revance now?	The operating name of the combined private company formed after Crown acquired Revance Therapeutics.
Did Revance acquire Crown?	No. Crown Laboratories acquired Revance Therapeutics and then adopted Revance as the combined company’s operating name.
Who developed Daxxify?	Revance Therapeutics developed daxibotulinumtoxinA-lanm and built its clinical and regulatory record.
Is Revance publicly traded?	No. The former Revance shares were delisted and deregistered after the February 2025 acquisition.
Who currently leads Revance?	Nadeem Moiz is Chief Executive Officer; Jeff Bedard is Founder and Executive Chairman. (Revance leadership)

Reference Card

Field	Reference point
Current operating name	Revance
Names readers may encounter	Revance; Revance Therapeutics, Inc.; Crown Laboratories, Inc.; Crown / Revance
Company status	Privately held combined company
Headquarters	Nashville, Tennessee, United States
Website	revance.com
Core toxin relationship	Developer, manufacturer, labeler, and commercial company context for Daxxify
Main brand node	Daxxify
Product identity	DaxibotulinumtoxinA-lanm, botulinum toxin type A

Revance’s current corporate history identifies the combined company as privately held and headquartered in Nashville. The same history preserves Johnson City, Tennessee as Crown Laboratories’ pre-combination headquarters context rather than presenting it as the combined company’s current headquarters. (Revance: About Us)

Company, Legal Entity, and Product Roles

The name Revance now works at more than one level. It is the combined company’s public-facing operating name, while Revance Therapeutics, Inc. and Crown Laboratories, Inc. continue to appear as legal entities within the group. Current Revance website terms identify Revance Therapeutics as the site operator and Crown Laboratories as an affiliate. (Revance terms of use)

Daxxify provides a separate regulatory layer. The current DailyMed record identifies Revance Therapeutics as the packager and lists it for active-ingredient manufacturing, finished-product manufacturing, and analysis. Those product-specific roles should not be replaced by the broader statement that Crown acquired the company. (DailyMed: DAXXIFY)

Layer	Name and role
Current corporate brand	Revance, the name used by the combined company
Acquirer and continuing affiliate	Crown Laboratories, Inc.
Historical developer and current product entity	Revance Therapeutics, Inc.
Botulinum toxin product	Daxxify (daxibotulinumtoxinA-lanm)

Development and Ownership Timeline

Revance developed daxibotulinumtoxinA Revance’s current corporate history traces the biotechnology company’s work on peptide-assisted delivery and the clinical development of daxibotulinumtoxinA. (Revance: About Us)
Daxxify received U.S. approvals in 2022 and 2023 FDA first approved Daxxify in 2022 for the temporary improvement of moderate to severe glabellar lines in adults. The U.S. indication expanded in 2023 to include treatment of cervical dystonia in adults. (FDA Drug Trials Snapshot; DailyMed: DAXXIFY)
Crown acquired Revance in February 2025 Crown completed a tender offer and second-step merger on February 6, 2025. Revance’s former Nasdaq-listed shares were then delisted and deregistered. (completion announcement)
The combined company adopted the Revance name in March 2025 Crown announced on March 31, 2025 that it would operate under the Revance name effective immediately. This was a corporate name transition, not a new Daxxify approval or formulation. (name-transition announcement)
Post-acquisition leadership changed Revance’s current leadership page identifies Nadeem Moiz as CEO and Jeff Bedard as Founder and Executive Chairman. It also lists Conor Gallagher, Ph.D. as Chief Scientific Officer, Nick Crowe as Chief Operating Officer, and Steve Kreider as EVP and Chief Revenue Officer for Aesthetics and Therapeutics. (Revance leadership)

Daxxify and U.S. Label Context

The DailyMed record updated January 7, 2026 continues to identify two U.S. indications: temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults, and treatment of cervical dystonia in adults. A corporate acquisition, rebrand, or broader portfolio announcement does not extend those labeled uses. (DailyMed: DAXXIFY)

Daxxify is formulated with the RTP004 peptide excipient. That is a product-identity fact, not evidence that it is universally safer, stronger, longer-lasting, or clinically superior. The U.S. prescribing information also states that Daxxify potency units are specific to its preparation and assay and are not interchangeable with units of other botulinum toxin products.

Person	Why the relationship matters
Mark Foley	Revance CEO during Daxxify’s original FDA approval and early commercialization period.
Nadeem Moiz	Current CEO, anchoring the combined company’s post-acquisition leadership.
Jeff Bedard	Crown founder and current Revance Executive Chairman, connecting the acquisition with the name-transition period.
Conor Gallagher, Ph.D.	Current Chief Scientific Officer, providing the post-acquisition science-leadership context.
Steve Kreider	Current revenue leader for aesthetics and therapeutics, including Daxxify commercialization.
Nick Crowe	Current Chief Operating Officer, relevant to operations, supply chain, production, and quality.

Market Interpretation

The Revance / Crown relationship is best understood as a sequence rather than two parallel companies competing around Daxxify: Revance Therapeutics developed the product; Crown acquired Revance Therapeutics; and the combined company adopted Revance as its operating name.

The broader Revance portfolio includes aesthetics, regenerative, and consumer-skincare businesses, but those adjacent businesses do not change the toxin relationship. Daxxify remains the company’s botulinum toxin brand, and its identity, indications, units, and safety information remain governed by product-specific regulatory sources.

Knowledge Check

1. Which statement correctly describes the 2025 Crown–Revance transaction and name transition?

A. Revance acquired Crown and retained its Nasdaq listing. B. Crown acquired Revance Therapeutics, then the combined company adopted the Revance operating name. C. The companies remained independent but licensed their names to each other. D. Crown changed Daxxify into a new botulinum toxin product.

2. Which name best identifies the current public-facing combined company?

A. Crown Therapeutics B. Revance Nasdaq Holdings C. Revance D. Daxxify Laboratories

3. What did the acquisition change for Daxxify?

A. Its corporate ownership context changed, but its product identity and label remained product-specific. B. Its units became directly convertible to other toxin products. C. Its U.S. indications automatically expanded across the Crown portfolio. D. Its nonproprietary name changed to CrownbotulinumtoxinA.

4. Which pair matches Daxxify's current U.S. labeled indications?

A. Adult glabellar lines and pediatric spasticity B. Adult cervical dystonia and chronic migraine C. Adult glabellar lines and chronic migraine D. Adult glabellar lines and adult cervical dystonia